BALAXI — Balaxi Pharmaceuticals Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapContrarian

Annual cashflow statement for Balaxi Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	88.7	443	545	569	20.2
Depreciation
Non-Cash Items	0.094	-8.82	6.78	62.8	-32.4
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-230	-437	-216	-589	39.9
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Payable / Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-141	0.032	341	60.8	48.7
Capital Expenditures	-1.83	-12.8	-53.2	-131	-6.93
Purchase of Fixed Assets
Other Investing Cash Flow Items	0	-47	-231	24.9	-3.54
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Change in Net Intangibles
Other Investing Cash Flow
Cash from Investing Activities	-1.83	-59.7	-284	-106	-10.5
Financing Cash Flow Items	—	-0.131	-1.42	-3.54	-14.8
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	181	36.5	-1.63	255	303
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	38.8	-23.2	55.3	210	341